Inflammation and Immunology: The Latest on Drug Development Targeting Atopic Dermatitis with Edward Nash, CG’s Biotechnology Senior Analyst

Journey Through the Growth Economy · Jun 3, 2025 · 30m

Edward Nash, CG’s Biotechnology Senior Analyst specializing in metabolic disease and I&I joins Michael Graham, Director of Research and Investment Strategy to discuss the biggest takeaways from his 2nd Annual I&I Symposium (short for Inflammation and Immunology). Nash walks us through his tenure in the space from his hands on experience in a lab focusing on rational drug design and his earliest days on Wall Street during the “Dot Com” Bubble, to his current role at Canaccord Genuity; along the way, he describes how biotechnology company valuations and the transition from clinic to drug…